Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

被引：7
|
作者：
Nichols, G. [1 ]
Mills, A. [2 ]
Grossberg, R. [3 ]
Lazzarin, A. [4 ]
Maggiolo, F. [5 ]
Molina, J. [6 ]
Pialoux, G. [7 ]
Wright, D. [8 ]
Ait-Khaled, M. [9 ]
Huang, J. [10 ]
Vavro, C. [1 ]
Wynne, B. [11 ]
Yeo, J. [9 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Anthony Mills MD Inc, Los Angeles, CA USA
[3] Montefiore Med Ctr, New York, NY USA
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[6] Hosp St Louis, Paris, France
[7] Hosp Tenon, Paris, France
[8] Cent Texas Clin Res, Austin, TX USA
[9] GlaxoSmithKline, London, England
[10] GlaxoSmithKline, Mississauga, ON, Canada
[11] GlaxoSmithKline, Philadelphia, PA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18112
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [21] Eptinezumab Reduced Migraine Frequency, Duration, and Pain Intensity Through Week 24: Results From the Phase 3 PROMISE-1 Trial
    Silberstein, Stephen
    McAllister, Peter
    Berman, Gary
    Cady, Roger
    Smith, Jeff
    Biondi, David
    Hirman, Joe
    NEUROLOGY, 2018, 90
  • [22] Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
    Calmy, Alexandra
    Sanchez, Tamara Tovar
    Kouanfack, Charles
    Mpoudi-Etame, Mireille
    Leroy, Sandrine
    Perrineau, Segolene
    Wandji, Martial Lantche
    Tata, Darius Tetsa
    Bassega, Pierette Omgba
    Bwenda, Therese Abong
    Varloteaux, Marie
    Tongo, Marcel
    Mpoudi-Ngole, Eitel
    Montoyo, Alice
    Mercier, Noemie
    LeMoing, Vincent
    Peeters, Martine
    Reynes, Jacques
    LANCET HIV, 2020, 7 (10): : E677 - E687
  • [23] PHASE 3 STUDY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR (MTP-I) LOMITAPIDE IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): 56-WEEK RESULTS
    Cuchel, M.
    Meagher, E.
    Marais, A. D.
    Blom, D. J.
    Theron, H. du Toit
    Shah, P. K.
    Hegele, R. A.
    Bloeden, L. T.
    Sasiela, W. J.
    Rader, D. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 14 - 14
  • [24] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
    Osiyemi, Olayemi
    De Wit, Stephane
    Ajana, Faiza
    Bisshop, Fiona
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Leone, Peter
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    George, Nisha
    Wynne, Brian
    Aboud, Michael
    van Wyk, Jean
    Smith, Kimberly Y.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (06) : 975 - 986
  • [25] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS
    Kavanaugh, A.
    Cutolo, M.
    Mease, P.
    Gladman, D.
    Adebajo, A.
    Gomez-Reino, J.
    Wollenhaupt, J.
    Schett, G.
    Lespessailles, E.
    Hu, C.
    Stevens, R.
    Edwards, C.
    Birbara, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 90 - 91
  • [26] Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196
    De Wit, S.
    Bonnet, F.
    Osiyemi, O.
    Bisshop, F.
    Olalla, J.
    Routy, J.
    Wyen, C.
    Moodley, R.
    Pappa, K.
    Wang, R.
    Oyee, J.
    Saggu, P.
    Letang, E.
    Wynne, B.
    Jones, B.
    Smith, K.
    Ait-Khaled, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 12 - 13
  • [27] Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study
    Rubin, David T.
    Dignass, Axel
    Allegretti, Jessica R.
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Zhan, Jia
    Zhang, Hongyan
    Rayyan, Yaser
    Saruta, Masayuki
    Balderramo, Domingo
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Hisamatsu, Tadakazu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S744 - S745
  • [28] Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study
    Correll, Christoph U.
    Stein, Evan
    Graham, Christine
    DiPetrillo, Lauren
    Akerman, Sarah
    Stanford, Arielle D.
    Jiang, Ying
    Yagoda, Sergey
    McDonnell, David
    Hopkinson, Craig
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S339 - S339
  • [29] Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: 24-week results from 2 randomized, double-blind phase 3 studies
    Rosmarin, D.
    Pandya, A. G.
    Grimes, P.
    Harris, J. E.
    Desai, S. R.
    Lebwohl, M.
    Ruer-Mulard, M.
    Passeron, T.
    Seneschal, J.
    Wolkerstorfer, A.
    Kornacki, D.
    Sun, K.
    Butler, K.
    Ezzedine, K.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 33 - 34
  • [30] SECUKINUMAB PROVIDES SIGNIFICANT IMPROVEMENT OF SPINAL PAIN AND LOWERS DISEASE ACTIVITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 24-WEEK RESULTS FROM A RANDOMISED CONTROLLED PHASE 3B TRIAL
    Marzo-Ortega, Helena
    Perella, Chiara
    Poddubnyy, Denis
    Pournara, Effie
    Zielinska, Agnieszka
    Baranauskaite, Asta
    Sadhu, Sanchayita
    Schulz, Barbara
    Rissler, Michael
    RHEUMATOLOGY, 2021, 60
12345